NCT03233711 2026-03-18
Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer
National Cancer Institute (NCI)
Phase 3 Active not recruiting
National Cancer Institute (NCI)
Emory University
Alliance for Clinical Trials in Oncology
Massachusetts General Hospital
Children's Oncology Group
M.D. Anderson Cancer Center
Shanghai Chest Hospital
NRG Oncology